Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxil and Rituximab in Magrath Regimen for Burkitt's Lymphoma
NCT00392990Phase 2Completed
- Sponsor
- Northwestern University
- Start
- Feb 2007
- Primary completion
- Dec 2011
- Modality
- Monoclonal Antibodies, Targeted Liposomes, Stealth (PEGylated) Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pegylated liposomal doxorubicin and rituximab in Burkitt lymphoma (BL) and Burkitt-like lymphoma (BLL) (2 arms), sponsored by Northwestern University. Primary endpoint: Overall Response Rate at 20 weeks. Started Feb 2007; status: completed.
02
Drugs
pegylated liposomal doxorubicinrituximab
03
Conditions
Burkitt lymphoma (BL)Burkitt-like lymphoma (BLL)
Beyond the preview
Go deeper on NCT00392990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00392990.